bih.button.backtotop.text
BROWSE BY TEST NAME
#
%
1
2
3
5
8
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code (รหัสการทดสอบ):
090-71-3417

Order Name (ชื่อการทดสอบ):
Caris - MI Tumor seek & PD-L1, tissue (FFPE) **

 
Specimen / Container (สิ่งส่งตรวจ/ภาชนะ):
Tissue/ Formalin-fixed paraffin-embedded (FFPE) block
 
Turnaround Time (ระยะเวลารอผล):
Received specimen to report 20-30 days (Slide received to report)
 
Useful For (ประโยชน์การทดสอบ):
MI Tumor Seek (test by NGS), plus PD-L1 testing.

PD-1 (test by IHC) is an immunosuppressive protein molecule that is upregulated on activated T-cells and other immune cells. It is activated by binding to its ligand, PD-L1, an action that results in intracellular responses that reduce T-cell activation. Reports of aberrant PD-L1 expression in cancer cells have spurred the development of PD-1 and PD-L1 inhibitors. The U.S. Food and Drug Administration (FDA) recently approved an anti-PD-1 therapy, pembrolizumab (Keytruda), for the treatment of advanced or unresectable melanoma. Another anti-PD-1 agent, nivolumab, was recently approved in Japan for the treatment of unresectable melanoma.
 
Methodology (วิธีการทดสอบ):
Next-generation sequencing (NGS)
 
Test List In Profile (การทดสอบใน Profile):
All Biomarker Analysis includes:
DNA Mutation, Copy Number Alterations, Insertions/Deletions    
Genomic Signatures: MSI, TMB
RNA Fusion Analysis
IHC: PD-L1
 
AliasesName (ชื่อเรียกอื่นๆ) :
Comprehensive Genomic Profiling, Tissue
 
 
 
Test Code (รหัสการทดสอบ):
090-71-3417

Order Name (ชื่อการทดสอบ):
Caris - MI Tumor seek & PD-L1, tissue (FFPE) **

 
Collection Specimen Or Container (สิ่งส่งตรวจ/ภาชนะ):
Tissue/ Formalin-fixed paraffin-embedded (FFPE) block
 
Specimen Testing Type (สิ่งส่งตรวจที่ใช้ในการทดสอบ):
NGS: FFPE block or 10 unstained slides with a minimum of 20% malignant origin for DNA and 10% malignant origin for RNA. Needle biopsy is also acceptable (4-6 cores).
IHC: 1 unstained slide at 4μm thickness from FFPE block, with evaluable tumor present, per IHC test
 
Sub Mission Container (ภาชนะส่งตรวจ):
Specimen collection kit
 
Rejection Criteria (เกณฑ์ปฏิเสธสิ่งส่งตรวจ):
Specimen was insufficient for testing (Low cellularity, Low tumor purity, DNA highly fragmentation, Low of RNA quality)
 
 
 
Test Code (รหัสการทดสอบ):
090-71-3417

Order Name (ชื่อการทดสอบ):
Caris - MI Tumor seek & PD-L1, tissue (FFPE) **

 
Method detail (วิธีการทดสอบ):
Next-generation sequencing (NGS)
 
Schedule (ตารางการทดสอบ):
N/A **Sent out to Caris, USA
 
Turnaround Time (ระยะเวลารอผล):
Received specimen to report 20-30 days (Slide received to report)
 
Performing Location (หน่วยงานที่ทำการทดสอบ):
Caris Life Sciences, USA
Referral Lab Services, Laboratory Department 14160-2
 
 
 
Test Code (รหัสการทดสอบ):
090-71-3417

Order Name (ชื่อการทดสอบ):
Caris - MI Tumor seek & PD-L1, tissue (FFPE) **

 
 
Reference Value (ค่าอ้างอิง):
An interpretive report will be provided.
 
Clinical Reference (เอกสารอ้างอิง):
www.carislifesciences.com (Retrieved: 25 Jun 2020)